Interleukin-18 as a Urinary Biomarker for Diagnosis of Hepatorenal Syndrome in Patients with Decompensated Liver Cirrhosis

Document Type : Original Article

Authors

1 Department of Clinical Pathology, National Liver Institute, Faculty of Medicine, El-Menoufia University, Shebin Elkom, Egypt

2 Department of Hepatology and Gastroenterology, National Liver Institute, Faculty of Medicine, El-Menoufia University, Shebin Elkom, Egypt

Abstract

Background: Hepatorenal syndrome [HRS] is a common complication that occurs in people with decompensated cirrhosis and may result in a higher chance of death if not addressed. HRS is a prevalent complication observed in individuals with decompensated cirrhosis which leads to an elevated risk of mortality if left untreated.
The aim of the work: To assess the ability of urinary interleukin-18 [IL-18] to be used as potential biomarker for HRS in patients with decompensated liver cirrhosis.
 Patients and Methods: 120 hospitalized patients with decompensated liver cirrhosis, either with or without HRS were participated in the study. Two groups of patients were identified: 60 patients who had HRS and 60 patients who did not have HRS.
Results: Group I exhibited a considerably elevated IL-18 level compared to Group II [57.7±19.7 vs. 19.1±7.93 ng/ mL] [P = 0.001]. At the cutoff point of IL-18, more than 30.1[ng/ mL], it had 96% sensitivity and 90% specificity in detecting HRS patients.
Conclusion: Urinary IL-18 may prove to be a valuable biomarker for identifying HRS in patients with decompensated liver cirrhosis, providing valuable insights for diagnosis and management in this clinical setting. 

Keywords

Main Subjects

Files

Share

How to cite

Statistics